Fierce Pharma

Acquisitive Sanofi keeps deals coming, laying out $2.2B for hepatitis vaccine maker Dynavax

Following a feud with activist investor Deep Track Capital in the first half of 2025, vaccine developer Dynavax Technologies ...
Seeking Alpha

Sanofi to get commercial control of RSV therapy nirsevimab in US, AstraZeneca to record $0.7B gain

AstraZeneca (NASDAQ:AZN), Sanofi (NASDAQ:SNY) and Swedish Orphan Biovitrum (Sobi) (OTCPK:BIOVF) updated their contracts related to developing and commercializing respiratory syncytial virus (RSV) ...
Hoodline

Sanofi Acquires Emeryville's Dynavax Technologies for $2.2 Billion, Bolstering Vaccine Portfolio Amid Industry Optimism

Sanofi plans to acquire Dynavax Technologies for $2.2 billion, offering a 39% premium on the latter's shares, which may ...
Insurancenewsnet.com

Press Release: Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance

Sanofi will continue to provide different programs to ensure access and affordability to patients depending on their coverage situations and will continue to monitor policy and market changes. Our ...
TipRanks on MSN

Sanofi to buy Dynavax in $2.2 billion push into adult vaccines

Sanofi ( ($SNY) ) has issued an announcement. On December 24, 2025, Sanofi announced an agreement to acquire Dynavax Technologies Corporation, a ...